TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAsmaa Hassan mohamed Abdel Mawjoud

About this trial

1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity.

Inclusion criteria:

1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).

b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Eligibility criteria

Qualifiers

None

Disqualifiers

Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Trial design

Treatments tested in this trial

  • Detection of TNFAIP3 gene expression by real time PCR.

Treatment groups

110 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Asmaa Hassan mohamed Abdel Mawjoud

Lead sponsor

Assiut University

Sponsor institution

Assiut University

Collaborator